Simultaneous Metformin and Sitagliptin Effect on Proteins Content Involved in Insulin Resistance in Human Adipose Tissue of Type 2 Diabetes: A Clinical Trial

Didehdar, Reza; Naghiaee, Yousof; Mohiti-Ardekani, Javad; Heiranizadeh, Naeimeh; Rahmanian, Masaoud

doi:10.18502/ijdo.v17i3.19266

Volume 17, Issue 3 (7-2025) IJDO 2025, 17(3): 175-181 | Back to browse issues page

‎ 10.18502/ijdo.v17i3.19266

Mendeley

Zotero

RefWorks

Didehdar R, Naghiaee Y, Mohiti-Ardekani J, Heiranizadeh N, Rahmanian M. Simultaneous Metformin and Sitagliptin Effect on Proteins Content Involved in Insulin Resistance in Human Adipose Tissue of Type 2 Diabetes: A Clinical Trial. IJDO 2025; 17 (3) :175-181
URL: http://ijdo.ssu.ac.ir/article-1-966-en.html

Simultaneous Metformin and Sitagliptin Effect on Proteins Content Involved in Insulin Resistance in Human Adipose Tissue of Type 2 Diabetes: A Clinical Trial

Reza Didehdar ^*

, Yousof Naghiaee

, Javad Mohiti-Ardekani

, Naeimeh Heiranizadeh

, Masaoud Rahmanian

Department of Biochemistry and Molecular Biology, Faculty of Medicine, International Campus of Shahid Saduoghi University of Medical Sciences, Yazd, Iran. Department of Biochemistry, Faculty of Medicine, Zabol University of Medical Sciences, Zabol, Iran.

Abstract: (17 Views)

Objective: Obesity ultimately results in a variety of metabolic changes, the most significant of which is insulin resistance, which is a contributing factor to both type 2 diabetes and permanent insulin resistance? The purpose of this study was to determine whether these two medications break down insulin resistance concurrently and, if so, what modifications are made to the levels of the targeted proteins in the insulin signaling pathway in type 2 diabetic adipose tissue in humans.
Materials and Methods: A clinical trial is described in this article. We used (sodium dodecyl sulfate poly-acrylamide gel electrophoresis (SDSPAGE) and western blot analyses to identify the presence of insulin resistance-related proteins Insulin Receptor Substrate-1 (IRS-1), phosphatidylinositol 3 kinase (PI3K), and Mammalian Target of Rapamycin (mTOR) in the adipose tissue of type 2 diabetic patients. We looked at six individuals who were receiving simultaneous treatment with metformin and sitagliptin for three months, four of whom returned after treatment.
Results: Increases in glucose disposal, decreases in serum glucose levels (P< 0.05), decreased insulin resistance (P< 0.05), and changes in serum insulin levels were seen after concurrent therapy with metformin and sitagliptin. Conversely, an increase in the proteins implicated in insulin resistance, including PI3K, mTOR, and IRS-1, was noted in the adipose tissue of diabetic individuals (P< 0.05).
Conclusion: The insulin resistance-related proteins IRS-1, PI3K, and mTOR in type 2 diabetic adipose tissue were markedly improved by concurrent metformin and sitagliptin treatment.

Keywords: Insulin Resistance, Metformin, Sitagliptin, Diabetes, Glucose transporter 4

Full-Text [PDF 602 kb] (7 Downloads)

Type of Study: Research | Subject: Special
Received: 2025/02/13 | Accepted: 2025/05/29 | Published: 2025/07/28

References

1. Zhang C, Klett EL, Coleman RA. Lipid signals and insulin resistance. Clinical lipidology. 2013;8(6):659-67. [DOI:10.2217/clp.13.67]

2. Guo S. Insulin signaling, resistance, and the metabolic syndrome: insights from mouse models to disease mechanisms. The Journal of endocrinology. 2014;220(2):T1-T23. [DOI:10.1530/JOE-13-0327]

3. Cline GW, Petersen KF, Krssak M, Shen J, Hundal RS, Trajanoski Z, et al. Impaired glucose transport as a cause of decreased insulin-stimulated muscle glycogen synthesis in type 2 diabetes. New England Journal of Medicine. 1999;341(4):240-6. [DOI:10.1056/NEJM199907223410404]

4. Hui H, Tang G, Go VL. Hypoglycemic herbs and their action mechanisms. Chinese Medicine. 2009;4:1-1. [DOI:10.1186/1749-8546-4-11]

5. World Health Organization. Use of glycated haemoglobin (HbA1c) in diagnosis of diabetes mellitus: abbreviated report of a WHO consultation. Geneva: World Health Organization [Internet]. 2011.

6. Inzucchi SE, Bergenstal RM, Buse JB, Diamant M, Ferrannini E, Nauck M, et al. Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach: update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes care. 2015;38(1):140-9. [DOI:10.2337/dc14-2441]

7. Sera N, Hida A, Imaizumi M, Nakashima E, Akahoshi M. The association between chronic kidney disease and cardiovascular disease risk factors in atomic bomb survivors. Radiation research. 2013;179(1):46-52. [DOI:10.1667/RR2863.1]

8. Carswell KA, Lee MJ, Fried SK. Culture of isolated human adipocytes and isolated adipose tissue. Methods in Molecular Biology (MIMB)2012:806:203-14. [DOI:10.1007/978-1-61779-367-7_14]

9. Beeson M, Sajan MP, Dizon M, Grebenev D, Gomez-Daspet J, Miura A, et al. Activation of protein kinase C-ζ by insulin and phosphatidylinositol-3, 4, 5-(PO4) 3 is defective in muscle in type 2 diabetes and impaired glucose tolerance: amelioration by rosiglitazone and exercise. Diabetes. 2003;52(8):1926-34. [DOI:10.2337/diabetes.52.8.1926]

10. Luna V, Casauban L, Sajan MP, Gomez-Daspet J, Powe JL, Miura A, Rivas J, Standaert ML, Farese RV. Metformin improves atypical protein kinase C activation by insulin and phosphatidylinositol-3, 4, 5-(PO 4) 3 in muscle of diabetic subjects. Diabetologia. 2006;49:375-82. [DOI:10.1007/s00125-005-0112-4]

11. Temofonte N, Sajan MP, Nimal S, Pastoor T, Fumero C, Casaubon L, et al. Combined thiazolidinedione-metformin treatment synergistically improves insulin signalling to insulin receptor substrate-1-dependent phosphatidylinositol 3-kinase, atypical protein kinase C and protein kinase B/Akt in human diabetic muscle. Diabetologia. 2009;52:60-4. [DOI:10.1007/s00125-008-1180-z]

12. Williams‐Herman D, Johnson J, Teng R, Golm G, Kaufman KD, Goldstein BJ, et al. Efficacy and safety of sitagliptin and metformin as initial combination therapy and as monotherapy over 2 years in patients with type 2 diabetes. Diabetes, Obesity and Metabolism. 2010;12(5):442-51. [DOI:10.1111/j.1463-1326.2010.01204.x]

13. Souza-Mello V, Gregorio BM, Cardoso-de-Lemos FS, de Carvalho L, Aguila MB, Mandarim-de-Lacerda CA. Comparative effects of telmisartan, sitagliptin and metformin alone or in combination on obesity, insulin resistance, and liver and pancreas remodelling in C57BL/6 mice fed on a very high-fat diet. Clinical science. 2010;119(6):239-50. [DOI:10.1042/CS20100061]

14. Karasik A, Aschner P, Katzeff H, Davies MJ, Stein PP. Sitagliptin, a DPP-4 inhibitor for the treatment of patients with type 2 diabetes: a review of recent clinical trials. Current medical research and opinion. 2008;24(2):489-96. [DOI:10.1185/030079908X261069]

15. Casaubon L, Sajan MP, Rivas J, Powe JL, Standaert ML, Farese RV. Contrasting insulin dose-dependent defects in activation of atypical protein kinase C and protein kinase B/Akt in muscles of obese diabetic humans. Diabetologia. 2006;49(12):3000-8. [DOI:10.1007/s00125-006-0471-5]

16. Kim YB, Ciaraldi TP, Kong A, Kim D, Chu N, Mohideen P, et al. Troglitazone but not metformin restores insulin-stimulated phosphoinositide 3-kinase activity and increases p110β protein levels in skeletal muscle of type 2 diabetic subjects. Diabetes. 2002;51(2):443-8. [DOI:10.2337/diabetes.51.2.443]

17. Farese RV, Sajan MP, Yang H, Li P, Mastorides S, Gower WR, et al. Muscle-specific knockout of PKC-λ impairs glucose transport and induces metabolic and diabetic syndromes. The Journal of clinical investigation. 2007;117(8):2289-301. [DOI:10.1172/JCI31408]